Develops hydrogel-based eye medicines, including DEXTENZA for surgical eye inflammation and pain and investigational AXPAXLI for retinal diseases, for patients treated by eye-care providers.
10-K for FY2025, filed Feb 5, 2026We are an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI, also known as OTX-TKI, our…View ↗
We also leverage the ELUTYX technology in our commercial product DEXTENZA, a corticosteroid approved by the U.S. Food and Drug…View ↗
DEXTENZA and our product candidates in clinical development generally incorporate therapeutic agents that have previously received…View ↗
Sells DEXTENZA to specialty distributors and directly to some surgery centers and physicians’ offices; payment for product sales is tied to delivery to the customer.
10-K for FY2025, filed Feb 5, 2026Our net product revenue is generated from the sale of DEXTENZA to specialty distributors, or SDs, for resale to certain ambulatory surgery…View ↗
Product RevenueView ↗
The Company recognizes revenue on product sales when the customer obtains control of the Company's product, which occurs at a point in time…View ↗
10-K for FY2025, filed Feb 5, 2026
FY2025 revenue by product or service ↗$52M
10-K for FY2025, filed Feb 5, 2026
$52M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product revenue, net
Sold outright
10-K for FY2025, filed Feb 5, 2026 |
100%
FY2022: 98%
|
Product revenue, net, FY2025
$51.8M Sources
|
Sold outright |
|
Collaboration revenue
|
0.3%
FY2022: 2.0%
|
Collaboration revenue, FY2025
$128K Sources
|
Sells DEXTENZA through specialty distributors to surgery centers, hospital outpatient departments and physicians’ offices, and directly to some surgery centers and physicians’ offices.
10-K for FY2025, filed Feb 5, 2026
No. It lost $265.9M in FY2025.
10-Q for Q3 FY2026, filed Nov 9, 2026
−$94.8MView ↗
10-Q for Q3 FY2026, filed Nov 9, 2026
Open tableView ↗
Growing. Revenue grew 19% in 4 years, from $43.5M in FY2021 to $52M in FY2025, about 5% a year.
More focused development pipeline
The older report described several development programs for dry eye disease, dry AMD and gene delivery alongside retinal and glaucoma candidates. The latest report centers its clinical pipeline on AXPAXLI for retinal disease and describes OTX-TIC as a program with next steps under evaluation.
10-K for FY2022, filed Mar 6, 2023 10-K for FY2025, filed Feb 5, 2026We are currently commercializing DEXTENZA, an intracanalicular insert for the treatment of both post-surgical ocular inflammation and pain…View ↗
OTX-DED, a dexamethasone intracanalicular insert being developed for the short-term treatment of the signs and symptoms of dry eye disease;View ↗
OTX-CSI, a cyclosporine intracanalicular insert being developed for the chronic treatment of dry eye disease;View ↗
A complement inhibitor program in preclinical development for the treatment of dry age-related macular degeneration, or dry AMD; andView ↗
A gene delivery program in preclinical development using our hydrogel technology to control the release of vectors such as adeno-associated…View ↗
We are an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI, also known as OTX-TKI, our…View ↗
Competes with Regeneron, Genentech, Eyepoint Pharmaceuticals, Kodiak Sciences, 4D Molecular Therapeutics, Adverum Biotechnologies, Eli Lilly and, RegenxBio, Alcon, Glaukos, Roche, Merck, Opus Genetics, AbbVie, PolyActiva, Spyglass Pharma, Icon Biosciences, pSvidia, and Rayner Surgical Group
10-K for FY2025, filed Feb 5, 2026The market for the treatment of wet AMD consists predominantly of five anti-VEGF, drugs, including four drugs that are approved for…View ↗
Loading...